-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2024-518243-38-00
5
2022-04-20
Fecal incontinence in female and male patients
-
2023-505438-85-00
5
2022-01-12
Acute myocardial infarction (AMI)
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2023-506618-29-00
4
2021-09-22
Advanced ovarian, breast, or prostate cancer
-
2024-512953-26-00
5
2021-07-06
intermediate-stage hepatocellular carcinoma
-
2024-515229-26-00
5
2021-05-21
eosinophilic esophagitis
-
2024-512671-12-00
10
2021-03-05
Unresectable head and neck squamous cell carcinoma, metastatic head an
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2024-516141-39-00
11
2020-09-25
anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-513734-38-00
5
2019-07-03
Prevention of breast cancer in women with a BRCA1 germline mutation
-
2024-512444-29-00
5
2019-05-07
patients who will undergo kidney, liver or kidney-pancreatic
transplan
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2024-513637-20-00
4
2017-03-24
Locally Advanced/Metastatic Squamous Cell Carcinoma of the Skin
-
2024-514556-32-00
5
2017-02-15
Adult critically ill patients with severe vitamin D deficiency
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-516078-31-00
10
2015-05-05
Recurrent and Primary Refractory Ewing Sarcoma
-
2024-515626-92-00
4
2013-10-18
recurrent/progressive medulloblastoma, ependymoma and atypical teratoi
-
2025-521067-13-00
5
2026-04-24
Atherosclerotic Cardiovascular Disease (ASCVD)
-
2025-520809-12-00
10
2025-10-16
Diabetic Macular Edema